Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

3.57USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$3.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
81,458
52-wk High
$14.09
52-wk Low
$3.31

Chart for

About

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel... (more)

Overall

Beta: --
Market Cap(Mil.): $145.30
Shares Outstanding(Mil.): 40.70
Dividend: --
Yield (%): --

Financials

  NBRV.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -2.27 -- --
ROI: -94.22 -3.79 13.23
ROE: -94.83 -5.32 15.28

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.

May 21 2018

UPDATE 3-Nabriva shares tumble as safety worries plague pneumonia drug

* Co to seek approval for drug in Q4 2018 (Adds analyst quote, updates stock price)

May 21 2018

BRIEF-Nabriva Announces Positive Results For Pneumonia Treatment

* NABRIVA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA

May 21 2018

Nabriva's pneumonia drug succeeds in late-stage study

May 21 Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.

May 21 2018

BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36

* NABRIVA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

May 08 2018

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

Mar 27 2018

BRIEF-Nabriva Appoints Jennifer Schranz As Chief Medical Officer

* NABRIVA THERAPEUTICS APPOINTS JENNIFER SCHRANZ, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

Mar 21 2018

BRIEF-Nabriva Therapeutics PLC Files For Mixed Shelf Of Upto $225 Million - SEC Filing

* NABRIVA THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source text (http://bit.ly/2HEW5CR) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 16 2018

BRIEF-Nabriva Therapeutics ‍had $86.9 Mln In Cash, Cash Equivalents as Of Dec 31

* NABRIVA THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

Mar 16 2018

Earnings vs. Estimates